MetrioPharm has released its annual report 2021. The company has provided an overview of the previous year’s achievements, the current state, and gives an outlook on the future business strategy. Thomas Christély, MetrioPharm’s CEO since last October, mentions in his preface that the company was able to increase its equity by a total of CHF 27.5 million in 2021.
Monthly Archives: May 2022
- 12.10.2022 MetrioPharm Starts Preclinical Experiments in Duchenne Muscular Dystrophy (DMD)
- 29.07.2022 Last Patient Out: MetrioPharm Completes Clinical Phase II Trial in COVID-19
- 02.03.2022 MetrioPharm surpasses 50% of enrollment in Phase II study in COVID-19
- 24.11.2021 MetrioPharm Signs European Commission Grant Agreement for €7.9 Million